Macrovascular Complications of Diabetes Mellitus

Pathobiology

• Hyperglycemia → advanced glycation end-products (AGEs), oxidative stress, protein kinase C activation
• Insulin resistance → compensatory hyperinsulinemia, impaired fibrinolysis
• Endothelial dysfunction → widespread, due to persistent hyperglycemia and insulin resistance
• Dyslipidemia → increased oxidation and glyoxidation of lipoproteins → enhanced foam cell formation
• Prothrombotic state → elevated plasminogen activator inhibitor-1 (PAI-1), platelet hyperaggregability
• Inflammation → elevated CRP, IL-6, TNF-α

Three Major Macrovascular Manifestations

1. Coronary Heart Disease (CHD)

• CAD occurs at a younger age with atypical presentations (silent MI is more common due to autonomic neuropathy)
• MI carries a worse prognosis; angioplasty gives less satisfactory results
• Increased risk of both ischemic and non-ischemic heart failure, and sudden death
• Multivessel coronary disease in diabetes: CABG is preferred over PCI with drug-eluting stents (lower death/nonfatal MI rates)
• Every 1% rise in HbA1c is associated with a 40% increase in cardiovascular mortality

• Hazard ratio for HF: ~1.2–1.7 in prediabetes; ~2.5 in diabetes
• Alterations include cardiac hypertrophy, left ventricular concentric remodeling, diastolic dysfunction (preceding systolic), and impaired myocardial energetics — not entirely attributable to CAD or hypertension
• Preferred agents: SGLT2 inhibitors (empagliflozin, canagliflozin) — consistently reduce HF hospitalization in HFrEF and HFpEF; GLP-1 RAs (liraglutide, semaglutide, dulaglutide) for established ASCVD

2. Cerebrovascular Disease

• Diabetes significantly increases stroke risk (both ischemic and hemorrhagic)
• Cerebral atherosclerosis progresses faster and is more extensive
• Stroke outcomes are worse in diabetic patients

3. Peripheral Vascular Disease (PVD) / Peripheral Arterial Disease (PAD)

• Diabetes and smoking are the strongest risk factors for PVD
• Risk is amplified by age, duration of diabetes, and concomitant peripheral neuropathy
• Gangrene of the lower extremities is ~100 times more common in diabetes than in the general population — Robbins
• PVD is a marker for systemic vascular disease (coronary, cerebral, renal); patients with diabetes + PVD have increased risk for MI or stroke regardless of PVD symptoms
• Symptoms may be attenuated or absent due to concurrent neuropathy (painless ulcers, Charcot joints)

• Ankle-Brachial Index (ABI): ratio of ankle to brachial systolic BP
  • ABI < 0.9 = 95% sensitivity for angiogram-positive PVD

• Clopidogrel 75 mg/d (superior to aspirin alone in diabetes + PVD)
• Exercise rehabilitation + cilostazol 100 mg bid for intermittent claudication (contraindicated in CHF)
• Severe ischemia: revascularization (percutaneous or surgical)

Risk Factors (Common in Diabetes)

Prevention & Management

Glycemic Control

• Target HbA1c <7% (≤53 mmol/mol), optimized early after diagnosis
• Avoid hypoglycemia (increases mortality risk in older patients with CV risk factors)
• Intensive glucose control reduces CV events by ~60% in T1DM; less clear in T2DM — however, SGLT2 inhibitors and some GLP-1 RAs reduce MACE and mortality independently of glycemic effects

Blood Pressure

• Target <130/80 mmHg
• First-line: ACE inhibitors or ARBs (additional renoprotective benefit)
• Add-on: β-blockers (caution: may mask hypoglycemia symptoms), CCBs, low-dose diuretics

Dyslipidemia

• High-intensity statin for known CVD or 10-year CV risk >7.5% → target LDL <70 mg/dL
• Moderate-intensity statin for others → target LDL <100 mg/dL
• Statin therapy slightly increases hyperglycemia (HR ~1.2), but CV benefit far outweighs risk

Antiplatelet Therapy

• Aspirin 75–81 mg/d: recommended for secondary prevention only (prior CV event)
• Aspirin NOT recommended for primary prevention in diabetes (no benefit, increased bleeding)
• Clopidogrel 75 mg/d: alternative in aspirin-intolerant high-risk patients

Novel Cardioprotective Agents

Key Points Summary

1. CHD → stroke → PVD are the three pillars of macrovascular disease in diabetes
2. Atherosclerosis is accelerated and morphologically identical to non-diabetic disease — but occurs earlier and with worse outcomes
3. Macrovascular complications are driven by multiple factors beyond hyperglycemia (dyslipidemia, hypertension, insulin resistance are equally important)
4. SGLT2 inhibitors and GLP-1 RAs have transformed management by offering cardiovascular protection beyond glucose lowering
5. Aggressive multifactorial risk factor control (glycemia + BP + lipids + smoking + antiplatelet) is the cornerstone of prevention